FDA Grants Fast Track Designation to Invikafusp Alfa in TMB-H Colorectal Cancer
Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer.
Related Articles
Payment stability bill introduced, would reverse 2025 cuts – American Society for Radiation Oncology (ASTRO)
Legislators introduced a Medicare payment stability bill that would reverse 2025 cuts
Men face substantial lifelong risk of oral HPV infection
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, a study provides information on…
AI Improves Mammography Tumor Detection
A study of more than 460,000 women shows that AI assistance can help radiologists spot nearly 18% more breast tumors on mammograms. The study also…
Advancement of First-Line Treatments on EGFR-Mutated NSCLC
As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients…
Editors’ Selections from Relevant Scientific Publications
Immune Response Pathways in FAP during cancer formation (by Esplin et al. via Nat Cancer)Multi-omic analysis of colon tissue specimens from people with familial adenomatous…
Rovadicitinib Shows Safety, Clinical Activity After Ruxolitinib Intolerance in Myelofibrosis
The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.
Tailoring CDS Tool Improves Biomarker Documentation in Cancer Treatment
Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.
Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer
Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.
Prognostic vs Predictive Factors in Oncology: Episode 1
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
